|
注册号: Registration number: |
ChiCTR2600126011 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-02 14:29:17 |
|
注册时间: Date of Registration: |
2026-06-02 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
单盲、随机、平行对照、多中心临床试验验证一次性带可吸收钉的电动痔吻合器用于治疗混合痔或Ⅱ~Ⅳ度内痔的有效性和安全性 |
|
Public title: |
A single-blind, randomized, parallel-controlled, multicenter clinical trial was conducted to evaluate the efficacy and safety of an electric hemorrhoid stapler with disposable absorbable staples for the treatment of mixed hemorrhoids or grade Ⅱ–Ⅳ internal hemorrhoids |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
单盲、随机、平行对照、多中心临床试验验证一次性带可吸收钉的电动痔吻合器用于治疗混合痔或Ⅱ~Ⅳ度内痔的有效性和安全性 |
|
Scientific title: |
A single-blind, randomized, parallel-controlled, multicenter clinical trial was conducted to evaluate the efficacy and safety of an electric hemorrhoid stapler with disposable absorbable staples for the treatment of mixed hemorrhoids or grade Ⅱ–Ⅳ internal hemorrhoids |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
樊志敏 |
研究负责人: |
王业皇 |
|
Applicant: |
Zhimin Fan |
Study leader: |
Yehuang Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 153 1204 5271 |
研究负责人电话:
Study leader's |
+86 153 1204 5271 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
fanzm@njucm.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
wangyehuang@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市秦淮区大明路157号 |
研究负责人通讯地址: |
江苏省南京市秦淮区大明路157号 |
|
Applicant address: |
No. 157, Daming Road, Qin'huai District, Nanjing, Jiangsu |
Study leader's address: |
No. 157, Daming Road, Qin'huai District, Nanjing, Jiangsu |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京市中医院 |
||
|
Applicant's institution: |
Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine |
||
|
研究负责人所在单位: |
南京市中医院 |
||
|
Affiliation of the Leader: |
Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025NJL001;2025NJL001-202508B-GZ04 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京市中医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-01-02 00:00:00 | ||
|
伦理委员会联系人: |
刘峥 |
||
|
Contact Name of the ethic committee: |
Zheng Liu |
||
|
伦理委员会联系地址: |
江苏省南京市秦淮区大明路157号 |
||
|
Contact Address of the ethic committee: |
No. 157, Daming Road, Qin'huai District, Nanjing, Jiangsu |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 132 2207 7296 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京市中医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市秦淮区大明路157号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 157, Daming Road, Qin'huai District, Nanjing, Jiangsu |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
施爱德(厦门)医疗器材有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Surgaid Medical (Xiamen) Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
混合痔 |
||||||||||||||||||||||
|
Target disease: |
Hemorrhoid |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究通过单盲、随机、平行对照、多中心临床试验验证一次性带可吸收钉的电动痔吻合器用于治疗混合痔或Ⅱ~Ⅳ度内痔的有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study verified the efficacy and safety of a disposable electrically powered hemorrhoid stapler with absorbable staples for the treatment of mixed hemorrhoids or grade Ⅱ–Ⅳ internal hemorrhoids through a single-blind, randomized, parallel-controlled, multicenter clinical trial. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 妊娠妇女、6 个月内有妊娠计划的妇女及其伴侣、哺乳期妇女; 2. 患有严重心、肺疾病者,或合并其他重症疾患者; 3. 患者及其监护人不能理解参与研究的要求; 4. 未受控制的心理疾病; 5. 明确对产品所用金属过敏; 6. 患者签署知情前曾参加过其他临床试验而未达到研究终点时限或达到研究终点时限但未满 6 个月; 7. 盆底失弛患者; 8. 患者符合产品禁忌证; 9. 研究者判断不适合入选的其他情况。 若符合以上任意一条,则不能入选。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pregnant women, women with pregnancy plans within 6 months, and their partners; breastfeeding women; 2. Those with severe heart or lung diseases, or those with other severe conditions; 3. Patients and their guardians cannot understand the requirements of participating in the study; 4. Uncontrolled mental disorders; 5. Clearly allergic to the metals used in the product; 6. Patients who have participated in other clinical trials before signing the informed consent but did not reach the study endpoint time limit or reached the study endpoint time limit but were less than 6 months; 7. Patients with pelvic floor dysfunction; 8. Patients who meet the contraindications of the product; 9. Other situations judged by the researcher as not suitable for inclusion. If any of the above conditions are met, the patient will not be eligible for inclusion. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-24 00:00:00至 To 2026-02-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-03-24 00:00:00 至 To 2025-10-09 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用随机系统进行简单随机化。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Simple randomization was carried out using a random system. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
施盲对象为受试者,因试验医疗器械与对照医疗器械制造材料不同,试验医疗器械吻合钉为可吸收材质,且外观差异明显,因此无法对研究者设盲,故本次试验采用单盲设计。 |
|
Blinding: |
The subjects were blinded. Due to the different manufacturing materials of the experimental medical device and the control medical device, the staples of the experimental medical device were made of absorbable materials and had obvious appearance differences. Therefore, it was impossible to blind the researchers. Thus, a single-blind design was adopted for this trial. |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据涉及器械专利信息,由于器械正在申请上市,因此选择不共享。临床评价部分的数据会为研究论文发表的形式公开。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data involves patent information on medical devices. As the devices are currently under application for market approval, we chose not to share them. The data from the clinical evaluation will be published in the form of research papers. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1、病例报告表记录要求 (1) 主要研究者应当确保按照申办者提供的指南,填写和修改病例报告表,确保病例报告表中的数据准确、完整、清晰和及时; (2) 病例报告表中报告的数据应当与源文件一致。病例报告表中数据的修改,应当确保初始记录清晰可辨,保留修改轨迹,修改者签名并注明日期; (3) 监查员监查临床试验是否遵循临床试验方案进行。确认所有病例报告表填写正确完整,并与原始资料一致。如有错误和遗漏,及时要求研究者修正; (4) 打印并收集受试者的检查检验报告单。临床试验方案规定受试者需要做的检查,其检查检验结果需填写至病例报告表的相应位置。 关于合并用药的特别说明: 采用试验用医疗器械进行治疗的受试者,使用影响伤口愈合的合并用药需要填写至对应的病例报告表、原始记录表合并用药页,具体药物类别如下:影响伤口愈合的药物:非甾体抗炎药、免疫抑制剂、细胞毒性药物等会对受试者吻合口愈合产生影响的合并用药。 2、原始记录书写要求 研究者及时填写原始资料,包括但不限于受试者一般情况、症状、体征、实验室检查结果、合并用药情况等。 3、病例报告表及病历的审核 申办者选择符合要求的监查员对病例报告表及病历进行审核,确认所有病例报告表填写正确,并与原始资料一致;所有错误或者遗漏均已改正或者注明,签名并注明日期;试验的病种、病例总数和病例的性别、年龄、治疗效果等均应当确认并记录。 4、临床试验资料保存 临床试验结束后,临床试验机构应当保存临床试验资料至临床试验结束后 10 年。申办者应当保存临床试验资料至无该医疗器械使用时。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. Requirements for the Case Report Form (1) The principal investigator should ensure that the case report form is filled out and modified in accordance with the guidelines provided by the sponsor, ensuring that the data in the case report form is accurate, complete, clear and timely; (2) The data reported in the case report form should be consistent with the source documents. Any modifications to the data in the case report form should ensure that the initial record is clearly identifiable, the modification trail is retained, the modifier signs and dates are noted; (3) The monitor inspects whether the clinical trial is conducted in accordance with the clinical trial protocol. It is confirmed that all case report forms are filled out correctly and completely, and are consistent with the original data. If there are errors or omissions, the investigator is required to correct them promptly; (4) Print and collect the examination and test reports of the subjects. For the examinations and tests that the subjects need to undergo as stipulated in the clinical trial protocol, the examination and test results should be filled in the corresponding positions of the case report form. Special instructions for combined medication: For subjects treated with investigational medical devices, the use of combined medications that affect wound healing should be filled in the corresponding case report form, original record sheet, and combined medication page. The specific drug categories are as follows: Medications that affect wound healing: non-steroidal anti-inflammatory drugs, immunosuppressants, cytotoxic drugs, etc., which will have an impact on the anastomotic wound healing of the subjects. 2. Requirements for the Writing of Original Records The investigator fills in the original data promptly, including but not limited to the general situation of the subjects, symptoms, signs, laboratory test results, and combined medication status. 3. Review of the Case Report Form and Medical Records The sponsor selects a qualified monitor to review the case report form and medical records, confirming that all case report forms are filled out correctly and consistent with the original data; all errors or omissions have been corrected or noted, signed and dated; the disease type, total number of cases, gender, age, and treatment effect of the cases should be confirmed and recorded. 4. Preservation of Clinical Trial Data After the clinical trial is completed, the clinical trial institution shall preserve the clinical trial data for 10 years after the end of the trial. The sponsor shall preserve the clinical trial data until the use of the medical device is no longer available. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |